dTMS to reduce antipsychotic-induced weight gain in schizophrenia
Official title: The Study of Improving Antipsychotic-induced Appetite by Deep Transcranial Magnetic Stimulation: The Effects of Improving Antipsychotic-induced Appetite by Single Session dTMS After Food Cue-induced Craving, A Randomized, Crossover and Sham-Controlled Trail
Run by Second Xiangya Hospital of Central South University · NCT07805980 · Data updated 2026-11-12
A non-invasive brain stimulation test to see if deep TMS can help reduce weight gain in people with schizophrenia who are on antipsychotics.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Second Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Status | Recruiting |
| Started | October 1, 2026 |
| Main results expected | May 1, 2027 |
| Study ends | June 1, 2027 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT07805980 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18-60 with schizophrenia who have gained about 7% body weight after antipsychotic treatment within the past 2 years and are on stable medication.
✕Probably not a fit
Individuals with rapid medication changes, other major mental illnesses, or contraindications to MRI/TMS may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial tests whether deep transcranial magnetic stimulation (dTMS) using an H4 coil can reduce weight gain associated with antipsychotic treatment in schizophrenia. It uses a randomized, single-session crossover design with sham control and a 30-person sample, including conditions with food-craving cues and without cues, to explore safety, tolerability, and efficacy. Participants undergo three sessions with washout periods, and outcomes include craving scores, subjective appetite, and behavioral measures of inhibitory control. The study also examines whether symptom provocation modulates the brain response to dTMS. Follow-ups occur at baseline and after each session.
Why it matters
Potential benefit: If successful, patients could experience less weight gain and better appetite control while on antipsychotics.
How similar studies have gone: Previous research suggests dTMS may help weight-related symptoms in some patients, but results are not yet conclusive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged between 18-60 * Meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for schizophrenia, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5). * Gaining body weight around 7% after intaking antipsychotics within 2 years * Participants were on a stable medication regimen at the time of enrollment * Written informed consent was obtained from both the participants and their legally authorized guardians Exclusion Criteria: * Participants who switch antipsychotic drugs (APDs) or require a dose modification exceeding 25% of the baseline dosage during the study period. * Diagnosed with other mental diseases in accordance with DSM-V * Comorbid with other severe physiological diseases * Active suicidal ideation * A history of alcohol or substance use disorder (or abuse) * Presence of metal implants or any other conditions contraindicated for magnetic resonance imaging (MRI) * Presence of intracranial metal or electronic devices, a personal or family history of epilepsy, or any other standard contraindications to deep transcranial magnetic stimulation * Receipt of regular repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), or weight-loss interventions within the past month * Pregnant or lactating women
Where it's running
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China Recruiting
Study contacts
- Study coordinator: Ping Shao
- Email: shp97jw@163.com
- Phone: +86-13755112445
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using accelerated dTMS to help with antipsychotic-related weight gain in schizophrenia
A randomized, sham-controlled trial tests whether accelerated dTMS can reduce weight gain caused by antipsychotic drugs in people with schizophrenia.
-
Using Lumateperone to improve motivation in patients with schizophrenia and psychosis
This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
XEP527 in stable schizophrenia: safety and how it behaves in the body
This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.
-
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.
-
Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder
This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.